The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards

被引:24
作者
Dong, Gaohong [1 ]
Huang, Bo [2 ]
Chang, Yu-Wei [3 ]
Seifu, Yodit [4 ]
Song, James [5 ]
Hoaglin, David C. [6 ]
机构
[1] iStats Inc, Long Isl City, NY 11101 USA
[2] Pfizer Inc, Groton, CT 06340 USA
[3] BeiGene Ltd, San Mateo, CA USA
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] BeiGene Ltd, Ridgefield Pk, NJ USA
[6] Univ Massachusetts, Sch Med, Dept Populat & Quantitat Hlth Sci, Worcester, MA USA
关键词
hazard ratio; landmark survival rate; log-rank test; prioritized pairwise comparisons; restricted mean survival time; GENERALIZED PAIRWISE COMPARISONS; PRIORITIZED OUTCOMES; CLINICAL-TRIALS; END-POINT;
D O I
10.1002/pst.1977
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The win ratio has been studied methodologically and applied in data analysis and in designing clinical trials. Researchers have pointed out that the results depend on follow-up time and censoring time, which are sometimes used interchangeably. In this article, we distinguish between follow-up time and censoring time, show theoretically the impact of censoring on the win ratio, and illustrate the impact of follow-up time. We then point out that, if the treatment has long-term benefit from a more important but less frequent endpoint (eg, death), the win ratio can show that benefit by following patients longer, avoiding masking by more frequent but less important outcomes, which occurs in conventional time-to-first-event analyses. For the situation of nonproportional hazards, we demonstrate that the win ratio can be a good alternative to methods such as landmark survival rate, restricted mean survival time, and weighted log-rank tests.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 26 条
[1]   Large sample inference for a win ratio analysis of a composite outcome based on prioritized components [J].
Bebu, Ionut ;
Lachin, John M. .
BIOSTATISTICS, 2016, 17 (01) :178-187
[2]   Generalized pairwise comparisons of prioritized outcomes in the two-sample problem [J].
Buyse, Marc .
STATISTICS IN MEDICINE, 2010, 29 (30) :3245-3257
[3]   Meta-Analysis of Clinical Trials With Sparse Binary Outcomes Using Zero-Inflated Binomial (ZIB) Models [J].
Dong, Cheng ;
Zhao, Yueqin ;
Tiwari, Ram .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (03) :228-238
[4]   The stratified win ratio [J].
Dong, Gaohong ;
Qiu, Junshan ;
Wang, Duolao ;
Vandemeulebroecke, Marc .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (04) :778-796
[5]   A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components [J].
Dong, Gaohong ;
Li, Di ;
Ballerstedt, Steffen ;
Vandemeulebroecke, Marc .
PHARMACEUTICAL STATISTICS, 2016, 15 (05) :430-437
[6]   Graphing the Win Ratio and its components over time [J].
Finkelstein, Dianne M. ;
Schoenfeld, David A. .
STATISTICS IN MEDICINE, 2019, 38 (01) :53-61
[7]  
Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO
[8]  
2-7
[9]   On the Fleming–Harrington test for late effects in prevention randomized controlled trials [J].
Garès V. ;
Andrieu S. ;
Dupuy J.F. ;
Savy N. .
Journal of Statistical Theory and Practice, 2017, 11 (3) :418-435
[10]   Some statistical considerations in the clinical development of cancer immunotherapies [J].
Huang, Bo .
PHARMACEUTICAL STATISTICS, 2018, 17 (01) :49-60